Cantor Fitzgerald initiated coverage of Janux Therapeutics with an Overweight rating and $100 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JANX:
- Janux Therapeutics price target raised to $48 from $24 at BofA
- Janux Therapeutics price target raised to $50 from $35 at H.C. Wainwright
- Janux Therapeutics reports Q4 EPS (25c), consensus (41c)
- Janux Therapeutics options imply 5.7% move in share price post-earnings
- Largest borrow rate increases among liquid names
